Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
A Multicenter Study of Long-Term Outcomes of Relapsing Polychondritis in Iran Publisher Pubmed



Jafarpour M1 ; Saberivand M1 ; Saemi M1 ; Sahebari M2 ; Seyedmardani S3 ; Salesi M4 ; Hosseinpoor S4 ; Faezi T5 ; Esalatmanesh K6 ; Hajialilo M1 ; Kolahi S1 ; Myrfeizi Z7 ; Khabbazi A1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Golgasht St., Tabriz, Iran
  2. 2. Rheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
  3. 3. Department of Internal Medicine, Urmia University of Medical Sciences, Urmia, Iran
  4. 4. Department of Internal Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  5. 5. Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Department of Internal Medicine, Kashan University of Medical Sciences, Kashan, Iran
  7. 7. Department of Internal Medicine, Mashad University of Medical Sciences, Mashhad, Iran

Source: Scientific Reports Published:2024


Abstract

Relapsing polychondritis (RP) is a systemic immune mediated disease characterized by recurrent episodes of inflammation in various cartilage-rich areas. RP may cause extensive tissue destruction and is associated with significant morbidity and mortality. In this multicenter study, we considered the remission status and long-term outcomes of RP in patients who were followed-up in six referral rheumatology centers in Iran. Outcomes of disease was assessed by remission status and RP induced damage. A total of 29 patients with RP were examined for enrollment in the study, and 26 patients with a minimum follow-up period of 6 months were included in the RP outcome analysis. Median time to control of symptoms and sustained remission were 5 and 23 weeks, respectively. Prednisolone was discontinued in 8 (30.8%) patients and medication-free remission was achieved in 7 (23.1%) patients. Regarding the disease course, 34.6% of patients had a relapsing–remitting course, 42.3% had a monophasic course, and 23.1% had an always-active course. Despite extensive treatment with immunosuppressive medications, RP induced damage was developed in 21 (80.8%) patients. Ear deformity and osteoporosis were the most common RP induced damage. Long-term remission and medications-free remission in RP is accessible. However, RP related damage occur in majority of patients. © The Author(s) 2024.
Related Docs
1. Ultrasonography of Articular and Periarticular Structures As a Relapse Predictor in Patients With Clinically Remitted Rheumatoid Arthritis, Indian Journal of Rheumatology (2020)
2. Different Duration of Colchicine for Preventing Recurrence of Gouty Arthritis, Journal of Research in Medical Sciences (2006)
3. Intravenous Pamidronate for Refractory Rheumatoid Arthritis, Journal of Research in Medical Sciences (2012)
4. Investigation of Recurrence of Joint Symptoms After Covid-19 in Patients With Rheumatoid Arthritis: Cross-Sectional Study, Journal of Research in Medical Sciences (2024)
5. Comparison of the Effect of Disease: Modifying Antirheumatic Drugs Alone or in Combination With Biologic Drugs in the Outcome of Patients With Rheumatoid Arthritis, Advanced Biomedical Research (2019)
6. Clinical Signs, Symptoms, and Severity of Covid-19 in Patients With Rheumatic Diseases During the Covid-19 Epidemic, Immunopathologia Persa (2024)
7. A Phase Iii, Randomized, Two-Armed, Double-Blind, Parallel, Active Controlled, and Non-Inferiority Clinical Trial to Compare Efficacy and Safety of Biosimilar Adalimumab (Cinnora®) to the Reference Product (Humira®) in Patients With Active Rheumatoid Arthritis, Arthritis Research and Therapy (2017)
8. Efficacy of Synbiotic Supplementation in Improving Rheumatoid Arthritis, Research in Pharmaceutical Sciences (2020)
Experts (# of related papers)
View all Related Experts
Mansour Salesi (4)
Peyman Mottaghi (2)